Literature DB >> 22108205

Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension.

Omar A Minai1, Ravi Gudavalli, Srinivas Mummadi, Xiaobo Liu, Kevin McCarthy, Raed A Dweik.   

Abstract

RATIONALE: Reduced heart rate recovery after exercise is associated with increased mortality in cardiopulmonary diseases.
OBJECTIVES: We sought to evaluate the association between heart rate recovery at 1 minute of rest (HRR1) after 6-min walk test (6MW test) and clinical worsening in patients with idiopathic pulmonary arterial hypertension (IPAH).
METHODS: HRR1 was defined as the difference in heart rate at the end of 6MW test and at 1 minute after completion of the 6MW test. Between August 1, 2009 and March 30, 2010, 75 consecutive patients with IPAH underwent 6MW test and were included in the analysis.
MEASUREMENTS AND MAIN RESULTS: Compared with patients with HRR1 ≥ 16 (n = 45 [60%]), those with HRR1 less than 16 (n = 30 [40%]) were more likely to have clinical worsening (odds ratio, 9.7; 95% confidence interval [CI], 3-30; P < 0.001) and shorter time to first clinical worsening event (TCW) (6.7 mo vs. 13 mo; P < 0.001) during follow-up. By multivariable analysis, the best predictors of clinical worsening were HRR1 less than 16 (hazard ratio, 5.2; 95% CI, 1.8-14.8; P = 0.002) and mean pulmonary arterial pressure (hazard ratio, 1.04; 95% CI, 1.007-1.08; P = 0.02). Compared with the distance walked during the 6MW test (6MWD), HRR1 less than 16 was a better predictor of clinical worsening (C statistic 0.757 vs. 0.703) and TCW (C index 0.730 vs. 0.696). The addition of HRR1 increased the ability of 6MWD to predict clinical worsening events.
CONCLUSIONS: HRR1 after 6MW test is a strong predictor of clinical worsening and TCW in patients with IPAH. The addition of HRR1 to 6MWD increases the capacity of 6MWD to predict clinical worsening and TCW in patients with IPAH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22108205     DOI: 10.1164/rccm.201105-0848OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  26 in total

1.  Carotid chemoreflex activity restrains post-exercise cardiac autonomic control in healthy humans and in patients with pulmonary arterial hypertension.

Authors:  Marcelle Paula-Ribeiro; Indyanara C Ribeiro; Liliane C Aranda; Talita M Silva; Camila M Costa; Roberta P Ramos; Jaquelina S Ota-Arakaki; Sergio L Cravo; Luiz E Nery; Michael K Stickland; Bruno M Silva
Journal:  J Physiol       Date:  2019-01-30       Impact factor: 5.182

Review 2.  Pulmonary arterial hypertension: the clinical syndrome.

Authors:  Yen-Chun Lai; Karin C Potoka; Hunter C Champion; Ana L Mora; Mark T Gladwin
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 3.  Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?

Authors:  Alison M MacKenzie; Andrew J Peacock
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 4.  Six-Minute Walk Test for Assessing Physical Functional Capacity in Chronic Heart Failure.

Authors:  Huiyun Du; Parichat Wonggom; Jintana Tongpeth; Robyn A Clark
Journal:  Curr Heart Fail Rep       Date:  2017-06

5.  Value of impedance cardiography during 6-minute walk test in pulmonary hypertension.

Authors:  Adriano R Tonelli; Laith Alkukhun; Vineesha Arelli; José Ramos; Jennie Newman; Kevin McCarthy; Bohdan Pichurko; Omar A Minai; Raed A Dweik
Journal:  Clin Transl Sci       Date:  2013-09-06       Impact factor: 4.689

6.  Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

Authors:  Samar Farha; Didem Saygin; Margaret M Park; Hoi I Cheong; Kewal Asosingh; Suzy Aa Comhair; Olivia R Stephens; Emir C Roach; Jacqueline Sharp; Kristin B Highland; Frank P DiFilippo; Donald R Neumann; W H Wilson Tang; Serpil C Erzurum
Journal:  JCI Insight       Date:  2017-08-17

7.  Heart rate recovery after maximal exercise is impaired in healthy young adults born preterm.

Authors:  Kristin Haraldsdottir; Andrew M Watson; Arij G Beshish; Dave F Pegelow; Mari Palta; Laura H Tetri; Melissa D Brix; Ryan M Centanni; Kara N Goss; Marlowe W Eldridge
Journal:  Eur J Appl Physiol       Date:  2019-01-11       Impact factor: 3.078

8.  Heart rate variability and heart rate recovery in lung cancer survivors eligible for long-term cure.

Authors:  Duc Ha; Atul Malhotra; Andrew L Ries; Wesley T O'Neal; Mark M Fuster
Journal:  Respir Physiol Neurobiol       Date:  2019-07-31       Impact factor: 1.931

9.  Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Laith Alkukhun; Xiao-Feng Wang; Mostafa K Ahmed; Manfred Baumgartner; Marie M Budev; Raed A Dweik; Adriano R Tonelli
Journal:  Respir Med       Date:  2016-06-02       Impact factor: 3.415

10.  Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension.

Authors:  Omar A Minai; Quyen Nguyen; Srinivas Mummadi; Esteban Walker; Kevin McCarthy; Raed A Dweik
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.